© 2003 by Oxford University Press
© 2003 Oxford University Press
ARTICLE |
Effect of Epidermal Growth Factor Receptor Inhibitor on Development of Estrogen Receptor–Negative Mammary Tumors
Affiliations of authors: Departments of Medicine and Molecular and Cellular Biology, Breast Center, Baylor College of Medicine, Houston, TX (CL, CS, YZ, JH, ES, JC, QS, HK, SH, SKM, CKO, PHB); M. D. Anderson Cancer Center, Houston (XX); AstraZeneca, Macclesfield, U.K. (AW).
Correspondence to: Powel H. Brown, MD, PhD, Baylor College of Medicine, One Baylor Plaza, MS 600, Houston, TX 77030 (e-mail: pbrown{at}breastcenter.tmc.edu)
Background: Although antiestrogens have been effective in preventing estrogen receptor (ER)-positive breast cancer, chemopreventive agents are still needed to prevent ER-negative breast cancer. Tyrosine kinase inhibitors are promising agents for the treatment and prevention of human cancers. ZD1839 (gefitinib or Iressa) is an orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that blocks signal transduction pathways in epithelial cells. We examined whether ZD1839 blocks signal transduction and prevents the development of ER-negative breast cancer. Methods: The ability of ZD1839 to block signal transduction in normal, immortalized, and malignant breast cells was assessed by western blotting with specific antibodies to detect phosphorylation of cytoplasmic signaling molecules. The effect of ZD1839 on growth of these breast cells was assessed with anchorage-dependent and anchorage-independent growth assays. Its effect on ER-negative mammary tumorigenesis was assessed in MMTV-erbB2 transgenic mice. All statistical tests were two-sided. Results: ZD1839 suppressed the phosphorylation of EGFR and mitogen-activated protein kinase in normal and malignant breast cells. ZD1839 treatment statistically significantly suppressed mammary tumorigenesis in MMTV-erbB2 transgenic mice; median time to tumor development was approximately 230 days in vehicle-treated mice and more than 310 days in mice treated with ZD1839 at 100 mg/kg (P<.001). ZD1839 reduced proliferation of normal breast cells by 20.3% (95% confidence interval [CI] = -13.7% to 44.2%) and of tumor cells by 42.0% (95% CI = 20.2% to 58.2%). ZD1839 also increased expression of the cell cycle regulator p27 in normal mammary tissue by 48.7% (95% CI = 27.0% to 74.2%) and in tumor tissue by 50.3% (95% CI = 35.8% to 66.7%). Conclusion: This study appears to provide the preclinical rationale for the development of these EGFR tyrosine kinase inhibitors for the prevention of human breast cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
Correspondence about this Article
- Re: Effect of Epidermal Growth Factor Receptor Inhibitor on Development of Estrogen Receptor–Negative Mammary Tumors
- Manuela Campiglio, Nicola Normanno, and Sylvie Ménard
J Natl Cancer Inst 2004 96: 715.[Extract] [Full Text] [PDF]
- RESPONSE: Re: Effect of Epidermal Growth Factor Receptor Inhibitor on Development of Estrogen Receptor-Negative Mammary Tumors
- Chunhua Lu, Syed K. Mohsin, Susan Hilsenbeck, Alan Wakeling, and Powel H. Brown
J Natl Cancer Inst 2004 96: 715-716.[Extract] [Full Text] [PDF]
Editorial about this Article
- Is There a Role for Epidermal Growth Factor Receptor Inhibitors in Breast Cancer Prevention?
- Gottfried E. Konecny, Cindy A. Wilson, and Dennis J. Slamon
J Natl Cancer Inst 2003 95: 1813-1815.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  K. Liby, R. Risingsong, D. B. Royce, C. R. Williams, M. M. Yore, T. Honda, G. W. Gribble, W. W. Lamph, N. Vannini, I. Sogno, et al. Prevention and Treatment of Experimental Estrogen Receptor-Negative Mammary Carcinogenesis by the Synthetic Triterpenoid CDDO-Methyl Ester and the Rexinoid LG100268 Clin. Cancer Res., July 15, 2008; 14(14): 4556 - 4563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Lubet, E. Szabo, K. Christov, A. M. Bode, M. E. Ericson, V. E. Steele, M. M. Juliana, and C. J. Grubbs Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes Mol. Cancer Ther., April 1, 2008; 7(4): 972 - 979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yan, Y. Lu, M. Wang, H. Vikis, R. Yao, Y. Wang, R. A. Lubet, and M. You Effect of an Epidermal Growth Factor Receptor Inhibitor in Mouse Models of Lung Cancer Mol. Cancer Res., December 1, 2006; 4(12): 971 - 981. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lanza-Jacoby, R. Burd, F. E. Rosato Jr., K. McGuire, J. Little, N. Nougbilly, and S. Miller Effect of Simultaneous Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 in HER-2/Neu-Positive Breast Cancer. Clin. Cancer Res., October 15, 2006; 12(20): 6161 - 6169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Liby, M. Rendi, N. Suh, D. B. Royce, R. Risingsong, C. R. Williams, W. Lamph, F. Labrie, S. Krajewski, X. Xu, et al. The Combination of the Rexinoid, LG100268, and a Selective Estrogen Receptor Modulator, Either Arzoxifene or Acolbifene, Synergizes in the Prevention and Treatment of Mammary Tumors in an Estrogen Receptor-Negative Model of Breast Cancer. Clin. Cancer Res., October 1, 2006; 12(19): 5902 - 5909. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sato, M. B. Vaughan, L. Girard, M. Peyton, W. Lee, D. S. Shames, R. D. Ramirez, N. Sunaga, A. F. Gazdar, J. W. Shay, et al. Multiple Oncogenic Changes (K-RASV12, p53 Knockdown, Mutant EGFRs, p16 Bypass, Telomerase) Are Not Sufficient to Confer a Full Malignant Phenotype on Human Bronchial Epithelial Cells Cancer Res., February 15, 2006; 66(4): 2116 - 2128. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T Chatterton Jr, E. T Mateo, N. Hou, A. W Rademaker, S. Acharya, V C. Jordan, and M. Morrow Characteristics of salivary profiles of oestradiol and progesterone in premenopausal women J. Endocrinol., July 1, 2005; 186(1): 77 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. H. Brown Breast Cancer Chemoprevention: Biomarker End-Point Trials Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 189 - 191. [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Dannenberg, S. M. Lippman, J. R. Mann, K. Subbaramaiah, and R. N. DuBois Cyclooxygenase-2 and Epidermal Growth Factor Receptor: Pharmacologic Targets for Chemoprevention J. Clin. Oncol., January 10, 2005; 23(2): 254 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Liu, F. Innocenti, M. H. Wu, A. A. Desai, M. E. Dolan, E. H. Cook Jr., and M. J. Ratain A Functional Common Polymorphism in a Sp1 Recognition Site of the Epidermal Growth Factor Receptor Gene Promoter Cancer Res., January 1, 2005; 65(1): 46 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. F Singer, G. Hudelist, W. Lamm, R. Mueller, K. Czerwenka, and E. Kubista Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors Endocr. Relat. Cancer, December 1, 2004; 11(4): 861 - 869. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Park, R. S. Kerbel, G. J. Kelloff, J. C. Barrett, B. A. Chabner, D. R. Parkinson, J. Peck, R. W. Ruddon, C. C. Sigman, and D. J. Slamon Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development Clin. Cancer Res., June 1, 2004; 10(11): 3885 - 3896. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Campiglio, N. Normanno, and S. Menard Re: Effect of Epidermal Growth Factor Receptor Inhibitor on Development of Estrogen Receptor-Negative Mammary Tumors J Natl Cancer Inst, May 5, 2004; 96(9): 715 - 715. [Full Text] [PDF]
|
|
|
|
|
|
C. Lu, S. K. Mohsin, S. Hilsenbeck, A. Wakeling, and P. H. Brown RESPONSE: Re: Effect of Epidermal Growth Factor Receptor Inhibitor on Development of Estrogen Receptor-Negative Mammary Tumors J Natl Cancer Inst, May 5, 2004; 96(9): 715 - 716. [Full Text] [PDF]
|
|
|
|
|
|
G. E. Konecny, C. A. Wilson, and D. J. Slamon Is There a Role for Epidermal Growth Factor Receptor Inhibitors in Breast Cancer Prevention? J Natl Cancer Inst, December 17, 2003; 95(24): 1813 - 1815. [Full Text] [PDF]
|
|